Coverage
-
September 23, 2015
A Pennsylvania federal judge nixed claims from consumers and wholesalers Wednesday that GlaxoSmithKline paid off generic rivals to keep cheaper versions of antidepressant Wellbutrin XL off the market, ruling that buyers couldn't show that the settlements that let the patent challenge continue violated antitrust law.
4 other articles on this case.
View all »